Sorted By Test Name - Mayo Medical Laboratories

FMI2
57186
RMA
81260
been shown for glioblastomas and alkylating agents such as Temodar (R) (temozolomide). Approximately
40% to 45% of glioblastoma multiforme (GBM) tumors exhibit MGMT gene methylation. Retrospective
studies have shown that detection of MGMT promoter methylation in tumor samples is associated with an
increased likelihood of a favorable response to temozolomide.
Reference Values:
Methylation Score:
unmethylated =2.00
Director Review:
Li Cai, PhD, FACMG
Director, Molecular Genetics
LabCorp Center for Molecular Biology and Pathology
Research Triangle Park, NC
1-800-533-0567
Test Performed By: LabCorp-Research Triangle Park
1912 Alexander Drive
P.O. Box 13973
Research Triangle Park, NC 27709
Clinical References: References: 1) Vlassenbroeck I. et al. Validation of Real-Time Methylation-
Specific PCR to Determine O(6)-Methylguanine-DNA Methyl- transferase Gene Promoter Methylation in
Glioma. J. Molecular Diagnostics 10; 4:332-337. 2008. 2) Hegi M. et al. MGMT Gene Silencing and
Benefit from Temo- zolomide in Glioblastoma. New England J Medicine 352; 10:997-1003. 2005. 3)
Brandes A. et al. MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of
Pseudoprogression After Concomitant Radiochemotheraphy in Newly Diagnosed Glioblastoma Patients.
J. Clinical Oncology 26; 13:2192-2197. 2008. 4) Hau P. et al. MGMT Methylation Status: The Advent of
Stratified Therapy in Glioblastoma. Disease Markers 23:97-104. 2007.
MI-2
Clinical Information: MI-2 is a Myositis specific Autoantibody and is seen in 5-10% of Myositis and
in 5% of Juvenile Myositis cases. MI-2 is also positive in classic dermatomyositis, mild to moderate
weakness with V and Shawl sign rashes, and cuticular overgrowth associated in adults; good response to
therapy.
Reference Values:
Negative
Test Performed by: RDL Reference Laboratory, Inc.
10755 Venice Boulevard
Los Angeles, CA 90034
Microalbumin, Random, Urine
Clinical Information: Diabetic nephropathy is a complication of diabetes and is characterized by
proteinuria (normal urinary albumin excretion is 300 mg/day). Before
overt proteinuria develops, albumin excretion increases in those diabetic patients who are destined to
develop diabetic nephropathy. Therapeutic maneuvers (eg, aggressive blood pressure maintenance,
particularly with angiotensin-converting enzyme inhibitors; aggressive blood sugar control; and possibly
decreased protein intake) can significantly delay, or possibly prevent, development of nephropathy. Thus,
there is a need to identify small, but abnormal, increases in the excretion of urinary albumin (in the range
of 30-300 mg/day, ie, microalbuminuria). The National Kidney Foundation guidelines for the
management of patients with diabetes and microalbuminuria recommend that all type 1 diabetic patients
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1206